Last Update 25 Feb 26

SOPH: Higher Implied P/E And New Partnerships Will Support Future Platform Adoption

Analysts have raised their price target on SOPHiA GENETICS by $1, citing updated assumptions on discount rate and long term profitability that result in a slightly higher implied future P/E of 79.26x.

Analyst Commentary

Analysts raising the price target by $1 are essentially saying that, based on their updated models, the shares now justify a slightly richer valuation, reflected in the implied future P/E of 79.26x. Here is how bullish and cautious voices are framing that move.

Bullish Takeaways

Bullish analysts view the higher implied P/E of 79.26x as acceptable for a company they see as having meaningful long term profitability potential, so they are comfortable assigning a modestly higher price target.
The updated discount rate assumptions suggest to bullish analysts that the risk profile, in their view, can support a slightly higher valuation multiple without breaking their risk and reward framework.
Supportive analysts see the model changes as a refinement rather than a major overhaul. For them, this reinforces conviction that the earlier thesis around execution and growth remains intact enough to justify the extra $1 in target price.
By explicitly tying the target to long term profitability assumptions, bullish analysts are signaling that they see a path for earnings to eventually support a P/E near the current implied level, even if the timing and magnitude are uncertain.

Bearish Takeaways

More cautious analysts are likely to focus on the absolute level of the implied P/E at 79.26x, which is high in simple terms, and may argue that this leaves limited room for error if execution around profitability or growth does not track internal forecasts.
The fact that a relatively small $1 change in price target is tied to adjustments in discount rate and long term margins can be read as a reminder that the valuation is sensitive to modeling inputs, which adds another layer of risk for investors.
Bearish analysts may question whether the long term profitability embedded in the higher multiple is realistic, and could argue that any slower than expected ramp in earnings would make a 79.26x implied P/E look demanding.
For investors who prefer clearer visibility on earnings power, the reliance on longer dated assumptions to justify the new target may be seen as a reason to stay cautious and focus on how near term execution tracks against those expectations.

What's in the News

SOPHiA GENETICS added two of the largest U.S. healthcare systems to its network, with the institutions planning genomic testing for up to 60,000 patients annually across the West Coast and Midwest using the SOPHiA DDM platform for hereditary cancers and rare diseases (Key Developments).
The two new U.S. health system partners intend to use SOPHiA DDM for Enhanced Exome analysis, covering more than 20,000 genes, with goals that include faster test turnaround, streamlined costs, and expanded internal research linked to AI driven precision medicine (Key Developments).
The company announced a collaboration with The University of Texas MD Anderson Cancer Center to co develop next generation sequencing oncology tests and bioinformatics pipelines that aim to translate complex genomic and RNA sequencing data into clinical insights for cancer care (Key Developments).
SOPHiA GENETICS and MD Anderson plan a series of research programs focused on tumor evolution, reliability of genomic testing, and matching patients to clinical trials or research options, with MD Anderson researchers leading the work in molecular pathology and laboratory medicine (Key Developments).
The company issued 2026 earnings guidance, indicating expected full year revenue between US$92m and US$94m, with year over year growth of approximately 20% to 22% (Key Developments).

Valuation Changes

Fair Value, modelled at $7.67 before, is unchanged in the latest update at $7.67.
Discount Rate has fallen slightly from 8.44% to 8.43%, reflecting a small adjustment in the risk assumptions used in the model.
Revenue Growth remains effectively flat, with the assumption holding at about 19.92% in both the prior and updated models.
Net Profit Margin is steady at roughly 6.93% in both the earlier and updated assumptions.
Future P/E has risen slightly from 78.16x to 79.26x, reflecting a modest increase in the implied valuation multiple discussed by analysts.

0 views

Key Takeaways

Rapid platform adoption and high-value partnerships are fueling recurring revenue growth, expanding usage, and opening new verticals for SOPHiA GENETICS.
Process efficiencies and automation are driving margin improvements and setting the company on a path toward profitability and greater operating leverage.
Persistent unprofitability, customer concentration, currency risks, competition, and stricter regulations threaten growth prospects, market share, and the ability to scale internationally.

Catalysts

About SOPHiA GENETICS

Operates as a cloud-native software technology company in the healthcare space.What are the underlying business or industry changes driving this perspective?

The accelerating adoption of precision medicine and personalized healthcare is directly driving record new customer signings for SOPHiA GENETICS, particularly among large academic medical centers and central labs globally, setting up strong future recurring revenue growth as these customers ramp implementations and usage of the SOPHiA DDM platform.
The exponential expansion in healthcare data generation, combined with increasing demand for interoperable, cloud-based analytics platforms, is enabling SOPHiA GENETICS to upsell higher-value multimodal applications (like MSK-ACCESS and enhanced exome products), leading to rising ASPs, higher average contract values, and improved gross and net margins over time.
SOPHiA GENETICS' major new multiyear partnership with AstraZeneca to deploy AI-powered predictive models and real-world data analytics is a significant forward-looking catalyst, expected to contribute meaningfully to topline revenue from late 2025 into 2026 and to validate the platform for additional large biopharma partnerships in the future.
The increasing integration of multimodal data analytics (genomics, radiomics, clinical) onto the SOPHiA DDM platform is unlocking new verticals, driving higher adoption and usage per customer, and supporting a visible pipeline/backlog, which should drive sustained improvements in earnings and net margins as scale builds.
Ongoing process improvements, automation, and cost discipline are materially lowering cash burn and enhancing gross margins (adjusted gross margin improved to 74.4%), positioning SOPHiA GENETICS for operating leverage and progression toward positive adjusted EBITDA and profitability over the next 2–3 years.

SOPHiA GENETICS Earnings and Revenue Growth

SOPHiA GENETICS Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming SOPHiA GENETICS's revenue will grow by 21.4% annually over the next 3 years.
Analysts are not forecasting that SOPHiA GENETICS will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate SOPHiA GENETICS's profit margin will increase from -105.3% to the average US Healthcare Services industry of 8.8% in 3 years.
If SOPHiA GENETICS's profit margin were to converge on the industry average, you could expect earnings to reach $10.9 million (and earnings per share of $0.15) by about September 2028, up from $-73.4 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 57.4x on those 2028 earnings, up from -3.2x today. This future PE is greater than the current PE for the US Healthcare Services industry at 54.8x.
Analysts expect the number of shares outstanding to grow by 1.72% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.09%, as per the Simply Wall St company report.

SOPHiA GENETICS Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent losses, increasing operating expenses, and continued adjusted EBITDA losses heighten pressure on SOPHiA GENETICS' path to profitability, raising the risk of shareholder dilution and limiting future R&D investment (impacts net margins and long-term earnings).
Heavy reliance on ongoing large customer signings and a relatively small core customer base increases concentration risk; loss of major accounts, slower-than-expected implementations, or inability to convert backlog could cause revenue growth to stall or reverse (impacts topline revenue and revenue growth rate).
Exposure to significant foreign exchange volatility-given most expenses are in Swiss francs/euros while reporting is in US dollars-creates unpredictable swings in reported results and could mask underlying margin weakness in unstable macro environments (impacts reported net margins and earnings consistency).
Intensifying competition in rare disease and oncology genomics, including recent competitor acquisitions to expand OUS (outside US) market presence, threatens SOPHiA GENETICS' pricing power, customer retention, and market share, potentially leading to increased churn and lower average revenue per user (impacts gross margins and revenue).
Broad secular risks such as stricter global data protection regulations, increased compliance costs, and geopolitical tensions restricting data sharing could hamper SOPHiA GENETICS' ability to scale worldwide, driving up costs and limiting international revenue expansion (impacts revenue growth and operating margins).

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $7.0 for SOPHiA GENETICS based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $6.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $124.6 million, earnings will come to $10.9 million, and it would be trading on a PE ratio of 57.4x, assuming you use a discount rate of 8.1%.
Given the current share price of $3.43, the analyst price target of $7.0 is 51.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on SOPHiA GENETICS?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Precision Medicine Advances Will Transform Global Healthcare Analytics